Checkpoint inhibitors do not kill cancers. They remove checkpoints which prevent activated T cells from doing this. Checkpoints put a brake on normal immunologic mechanisms to eliminate cancers.
Waning of PD1 anticancer effect can be due to T cell exhaustion which can be overcome by our fusion protein, eftilagimod.
Eftilagimod allows reprogramming cellular immunity adapting to changing antigen environments. This is active immunotherapy c/w CAR T cell passive immunotherapies.
This paper points out that PD1 monotherapy may already be outdated and there is a need to include eftilagimod or similar therapies for sustained improvements.
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-669
-
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
-0.005(1.56%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
32.0¢ | 32.0¢ | 31.5¢ | $502.0K | 1.580M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1658 | 34.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
29.5¢ | 21734 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
39 | 191712 | 0.315 |
19 | 476574 | 0.310 |
22 | 396872 | 0.305 |
29 | 572023 | 0.300 |
7 | 162100 | 0.295 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 139264 | 12 |
0.325 | 300408 | 12 |
0.330 | 137809 | 7 |
0.335 | 68276 | 4 |
0.340 | 113046 | 5 |
Last trade - 15.59pm 11/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |